结构化报告系统实现跨经验水平可重复的胶质瘤分子分型与风险分层影像预测
该研究基于141例TCGA训练集和131例三级医院验证集,由3名1-7年经验神经放射科医生使用结构化报告系统评估MRI特征,以预测胶质瘤分子分型与风险分层。结果显示坏死、T2/FLAIR不匹配、内囊变和主导强化模式具有高可重复性,对IDH野生型胶质母细胞瘤、IDH突变/1p19q共缺失少突胶质细胞瘤和IDH突变弥漫性星形细胞瘤有较高预测效能,而IDH野生型低级别胶质瘤和IDH突变胶质母细胞瘤难以通过视觉分析识别。
要点
- 结构化报告系统可提高MRI特征评估的可重复性,坏死、T2/FLAIR不匹配、内囊变和主导强化模式一致率>50%。
- T2/FLAIR不匹配且无坏死对IDH突变弥漫性星形细胞瘤预测AUC达0.95。
- 主导强化对IDH野生型胶质母细胞瘤预测AUC达0.92-0.93,内囊变或坏死对少突胶质细胞瘤预测AUC为0.83-0.84。
关键影像表现/征象
- 可重复的影像参数包括坏死存在、T2/FLAIR不匹配、内囊变和主导强化模式,读者间一致率>50%。
- 风险5型(IDH野生型胶质母细胞瘤)的主要预测征象为主导强化。
- 风险2型(IDH突变弥漫性星形细胞瘤)的主要预测征象为T2/FLAIR不匹配且无坏死。
- 风险1型(IDH突变/1p19q共缺失少突胶质细胞瘤)的主要预测征象为内囊变或坏死。
- 风险3型和4型(IDH突变胶质母细胞瘤和IDH野生型弥漫性星形细胞瘤)难以通过视觉分析预测。
诊断标准与关键数值
- 风险5型(IDH野生型胶质母细胞瘤)预测:主导强化,验证集AUC reader1为0.92、reader2为0.93。
- 风险2型(IDH突变弥漫性星形细胞瘤)预测:T2/FLAIR不匹配且无坏死,验证集AUC reader1为0.95、reader2为0.95。
- 风险1型(IDH突变/1p19q共缺失少突胶质细胞瘤)预测:内囊变或坏死,验证集AUC reader1为0.84、reader2为0.83。
临床应用与阅片要点
- 日常阅片应采用结构化报告系统评估坏死、T2/FLAIR不匹配、内囊变和主导强化模式,以提高可重复性。
- 对于IDH野生型低级别胶质瘤和IDH突变胶质母细胞瘤,视觉分析预测困难,需结合分子检测。
局限性
- 风险3型和4型难以通过视觉分析预测,限制了影像分型的全面性。
- 研究为回顾性设计,验证集来自单中心。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine reproducible MRI parameters predictive of molecular subtype and risk stratification in glioma and develop a structured reporting system.
METHODS: All study patients were initially diagnosed with glioma, 141 from the Cancer Genome Atlas and 131 from our tertiary institution, as training and validation sets, respectively. Images were analyzed by three neuroradiologists with 1-7 years of experience. MRI features including contrast enhancement pattern, necrosis, margin, edema, T2/FLAIR mismatch, internal cyst, and cerebral blood volume higher than normal cortex were reported using a structured reporting system. The pathology was stratified into five risk types: (1) oligodendroglioma, isocitrate dehydrogenase [IDH]-mutant, 1p19q co-deleted; (2) diffuse astrocytoma, IDH-mutant, grade II-III; (3) glioblastoma, IDH-mutant, grade IV; (4) diffuse astrocytoma, IDH-wild, grade II-III; and (5) glioblastoma, IDH-wild, grade IV. Significant predictors were selected using multivariate logistic regression, and diagnostic performance was tested using a validation set.
RESULTS: Reproducible imaging parameters exhibiting > 50% agreement across readers included the presence of necrosis, T2/FLAIR mismatch, internal cyst, and predominant contrast enhancement. In the validation set, prediction of risk type 5 exhibited the highest diagnostic performance with AUCs of 0.92 (reader 1) and 0.93 (reader 2) with predominant enhancement, followed by risk type 2 with AUCs of 0.95 and 0.95 with T2/FLAIR mismatch sign and no necrosis, and risk type 1 with AUCs of 0.84 and 0.83 with internal cyst or necrosis. Risk types 3 and 4 were difficult to visually predict.
CONCLUSIONS: Imaging parameters with high reproducibility enabling prediction of IDH-wild-type glioblastoma, IDH-mutant/1p19q co-deletion oligodendroglioma, and IDH-mutant diffuse astrocytoma were identified.
KEY POINTS: • Reproducible MRI parameters for determining molecular subtypes of glioma included the presence of necrosis, T2/FLAIR mismatch, internal cyst, and predominant contrast enhancement. • IDH-wild type glioblastoma, IDH-mutant/1p19q co-deletion oligodendroglioma, and IDH-mutant low-grade astrocytoma were identified using MRI parameters with high inter-reader reproducibility. • Identification of IDH-wild type low-grade glioma and IDH-mutant glioblastoma was difficult by visual analysis.
引用
- Nam YK, Park JE, Park SY, et al. Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system. Eur Radiol. 2021. PMID: 34374800. doi:10.1007/s00330-021-08015-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。